| 亞洲大學 |
2014 |
Gelsolin ;GSN) induces cardiomyocyte hypertrophy and BNP expression via p38 signaling and GATA-4 transcriptional factor activation.
|
Hu, Wei-Syun;Hu, Wei-Syun;Tsung-Jung, H;Ho, Tsung-Jung;白培英;Chun, Li-Chin;Chung, Li-Chin;Kuo, Chia-Hua;Kuo, Chia-Hua;Sheng-Huang;Chang, Sheng-Huang;蔡輔仁;Tsai, Fuu-Jen;蔡長海; |
| 臺大學術典藏 |
2018-09-10T03:26:43Z |
Gelsolin binding and cellular presentation of lysophosphatidic acid
|
Goetzl, E.J.; Lee, H.; Azuma, T.; Stossel, T.P.; Turck, C.W.; Karliner, J.S.; HSIN-YU LEE |
| 國立成功大學 |
2014-04 |
Gelsolin expression modulates TGF-beta induced cell differentiation and epithelial to mesenchymal transition in breast cancer cells
|
Liou, Ying-Ming; Chen, Zhi-Yuan; Shieh, Dar-Bin; Chiu, Kung-Ying |
| 國家衛生研究院 |
2014-12 |
Gelsolin regulates cisplatin sensitivity in human head-and-neck cancer
|
Wang, PW;Abedini, MR;Yang, LX;Ding, AA;Figeys, D;Chang, JY;Tsang, BK;Shieh, DB |
| 國立成功大學 |
2014-12-15 |
Gelsolin regulates cisplatin sensitivity in human head-and-neck cancer
|
Wang, Pei-Wen; Abedini, Mohammad R.; Yang, Li-Xing; Ding, Ann-Ann; Figeys, Daniel; Chang, Jang-Yang; Tsang, Benjamin K.; Shieh, Dar-Bin |
| 國立成功大學 |
2015 |
Gelsolin 參與頭頸癌化療藥物敏感性的調控機制以及後續抗藥性分子診斷及抗抗藥性治療的奈米劑型開發
|
謝達斌; 吳炳慶; 黃則達 |
| 國立成功大學 |
2016 |
Gelsolin 參與頭頸癌化療藥物敏感性的調控機制以及後續抗藥性分子診斷及抗抗藥性治療的奈米劑型開發
|
謝達斌;黃則達;吳炳慶 |
| 國立成功大學 |
2016-08-15 |
Gelsolin 在慢性腎臟病中扮演的角色: 足細胞
|
游佳蓉; Yu, Jia-Rong |
| 國立成功大學 |
2014-10-24 |
Gelsolin 在頭頸癌中調控含鉑抗癌藥物治療的敏感度
|
王佩文;Abedini, Mohammad R.;楊理行;丁安安;Figeys, Daniel;張俊彥;Tsang, Benjamin K.;謝達斌 |
| 嘉南藥理大學 |
2018-07 |
Gelsolin-like Actin-capping Protein (CapG) Overexpression in the Cytoplasm of Human Hepatocellular Carcinoma, Associated with Cellular Invasion, Migration and Tumor Prognosis
|
Tsai, Tsung-Jung; Chao, Wen-Ying; Chen, Chien-Chin; Chen, Yi-Ju; Lin, Ching-Yen; Lee, Ying-Ray |
| 國立成功大學 |
2005-07-04 |
Gelsolin在口腔癌細胞侵犯 貼附和局部移動之研究
|
邵鈞義; Shau, Jiun-Yi |
| 國立成功大學 |
2014-08-14 |
Gelsolin對頭頸癌化療抗藥性之影響及其分子機制之探討
|
王佩文; Wang, Pei-Wen |
| 國立成功大學 |
2003-06-27 |
Gelsolin扮演在口腔癌化過程與上皮細胞分化之角色
|
陳藝文; Chen, Yi-Wen |
| 國立成功大學 |
2004 |
Gelsolin於正常人類口腔上皮及口腔癌細胞之運動、凋亡及分化所扮演的角色及分子機轉之探討
|
謝達斌 |
| 國立成功大學 |
2008-07-28 |
Gelsolin表現對基因剔除鼠之病理表現型與腫瘤發展之影響
|
張佑民; Chang, You-Min |
| 東方設計學院 |
2008-12-18 |
GEL推理複雜性檢核表之初探
|
許照紅; 許德發; 許瑞珍; 吳淨淩; (東方技術學院食品科技系) |
| 東方設計學院 |
2008-12 |
GEL推理複雜性檢核表之初探
|
許照紅; 許德發; 許瑞珍; 吳淨淩; (東方技術學院食品科技系); (東方技術學院化妝品應用與管理系) |
| 國立成功大學 |
1976-05 |
GEM-ACV及水裙之種類
|
馮小川 |
| 國立交通大學 |
2014-12-08T15:42:08Z |
GEM: A Gaussian evolutionary method for predicting protein side-chain conformations
|
Yang, JM; Tsai, CH; Hwang, MJ; Tsai, HK; Hwang, JK; Kao, CY |
| 國立臺灣大學 |
2002 |
GEM: A Gaussian evolutionary method for predicting protein side-chain conformations
|
Yang, Jinn-Moon; Tsai, Chi-Hung; Hwang, Ming-Jing; Tsai, Huai-Kuang; Hwang, Jenn-Kang; Kao, Cheng-Yan |
| 國立臺灣海洋大學 |
2002 |
GEM: a Gaussian Evolutionary Method for predicting protein side-chain conformations
|
Jinn-Moon Yang; Chi-Hung Tsai; Ming-Jing Hwang; Huai-Kuang Tsai; Jenn-Kang Hwang; Cheng-Yan Kao |
| 國立交通大學 |
2014-12-08T15:21:02Z |
GemAffinity: A Scoring Function for Predicting Binding Affinity and Virtual Screening
|
Hsu, Kai-Cheng; Chen, Yen-Fu; Yang, Jinn-Moon |
| 國立交通大學 |
2014-12-08T15:22:08Z |
GemAffinity: a scoring function for predicting binding affinity and Virtual Screening
|
Hsu, Kai-Cheng; Chen, Yen-Fu; Yang, Jinn-Moon |
| 中華大學 |
1998 |
GEMCAB：一個對於可測試性設計的性能標桿電路
|
趙智德; Zhao, Zhi De |
| 臺北醫學大學 |
2005 |
Gemcitabine /Carboplatin chemotherapy for Pure Small Cell Carcinoma of Prostate
|
陳冠州; Chen KC; Chiu AW; Chiang HS; Chu JS; Cheng CJ; |
| 國立臺灣大學 |
2002 |
Gemcitabine and Cisplatin in a Multimodality Treatment for Locally Advanced Non-Small Cell Lung Cancer
|
楊志新; 李元麒; 雷德; 許駿; 鄭安理; 陳育民; 陸坤泰; 彭瑞鵬; 楊泮池; YANG, CHIH-HSIN; LEE, YUNG-CHIE; LUI, LOUIS TAK; HSU, CHIUN; CHENG, ANN-LII; CHEN, YU-MING; LUH, KWEN-TAY; PENG, JUI-PENG; YANG, PAN-CHYR |
| 臺大學術典藏 |
2020-05-26T09:27:31Z |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
|
Perng R.-P.; Chih-Hsin Yang;Tsai C.M;Wang L.S;Lee Y.C;Chang C.J;Lui L.T;Yen S.H;Hsu C;Cheng A.L;Liu M.Y;Chiang S.C;Chen Y.M;Luh K.T;Huang M.H;Yang P.-C;Perng R.-P.; CHIH-HSIN YANG; Tsai C.M; Wang L.S; Lee Y.C; Chang C.J; Lui L.T; Yen S.H; Hsu C; Cheng A.L; Liu M.Y; Chiang S.C; Chen Y.M; Luh K.T; Huang M.H; Yang P.-C |
| 臺大學術典藏 |
2020-04-10T12:51:31Z |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
|
Yang C.H.;Tsai C.M.;Wang L.S.;Lee Y.C.;Chang C.J.;Lui L.T.;Yen S.H.;Chiun Hsu;Cheng A.L.;Liu M.Y.;Chiang S.C.;Chen Y.M.;Luh K.T.;Huang M.H.;Yang P.-C.;Perng R.-P.; Perng R.-P.; Yang P.-C.; Luh K.T.; Huang M.H.; Chen Y.M.; Chiang S.C.; Liu M.Y.; Cheng A.L.; Chiun Hsu; Tsai C.M.; Wang L.S.; Lee Y.C.; Chang C.J.; Lui L.T.; Yen S.H.; Yang C.H. |
| 臺大學術典藏 |
2020-12-02T02:36:06Z |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
|
Yang C.H.;Tsai C.M.;Wang L.S.;Lee Y.C.;Chang C.J.;Lui L.T.;Yen S.H.;Hsu C.;Cheng A.L.;Liu M.Y.;Chiang S.C.;Chen Y.M.;Luh K.T.;Huang M.H.;Pan-Chyr Yang;Perng R.-P.; Yang C.H.; PAN-CHYR YANG |
| 臺大學術典藏 |
2021-05-26T03:35:12Z |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
|
Yang C.H.; Tsai C.M.; Wang L.S.; Lee Y.C.; Chang C.J.; Lui L.T.; Yen S.H.; Hsu C.; Cheng A.L.; Liu M.Y.; Chiang S.C.; Chen Y.M.; KWEN-TAY LUH; Huang M.H.; Yang P.-C.; Perng R.-P. |
| 臺大學術典藏 |
2021-09-01T02:02:28Z |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
|
Yang C.H.; Tsai C.M.; Wang L.S.; Lee Y.C.; Chang C.J.; Lui L.T.; Yen S.H.; Hsu C.; ANN-LII CHENG; Liu M.Y.; Chiang S.C.; Chen Y.M.; Luh K.T.; Huang M.H.; Yang P.-C.; Perng R.-P. |
| 國立臺灣大學 |
2007 |
Gemcitabine and Ifosfamide as a Second-Line Treatment for Cisplatin- Refractory Metastatic Urothelial Carcinoma: A Phase Ii Study
|
林家齊; 徐志宏; 黃昭淵; 耿孝宜; 蔡育傑; 黃國皓; 鄭安理; 蒲永孝; LIN, CHIA-CHI; HSU, CHIH-HUNG; HUANG, CHAO-YUAN; KENG, HSIAO-YI; TSAI, YU-CHIEH; HUANG, KUO-HOW; CHENG, ANN-LII; PU, YEONG-SHIAU |
| 國立臺灣大學 |
2007-04 |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study
|
Lin, Chia-Chi; Chih-Hung; Hsu; Huang, Chao-Yuan; Keng, Hsiao-Yi; Tsai, Yu-Chieh; Huang, Kuo-How; Cheng, Ann-Lii; Pu, Yeong-Shiau |
| 臺大學術典藏 |
2018-09-10T06:13:47Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin, Chia-Chi;Chih-Hung;Hsu;Huang, Chao-Yuan;Keng, Hsiao-Yi;Tsai, Yu-Chieh;Huang, Kuo-How;Cheng, Ann-Lii;Pu, Yeong-Shiau; Lin, C.-C. and Hsu, C.-H. and Huang, C.-Y. and Keng, H.-Y. and Tsai, Y.-C. and Huang, K.-H. and Cheng, A.-L. and Pu, Y.-S.; Lin, Chia-Chi; CHAO-YUAN HUANG; CHIH-HUNG HSU; Chih-Hung; Hsu; KUO-HOW HUANG; YU-CHIEH TSAI; Huang, Chao-Yuan; ANN-LII CHENG; Keng, Hsiao-Yi; Tsai, Yu-Chieh; YEONG-SHIAU PU; Huang, Kuo-How; Cheng, Ann-Lii; Pu, Yeong-Shiau |
| 臺大學術典藏 |
2020-05-25T07:35:33Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Chia-Chi Lin; Hsu C.-H; Huang C.-Y; Keng H.-Y; Tsai Y.-C; Huang K.-H; Cheng A.-L; Pu Y.-S. |
| 臺大學術典藏 |
2021-01-28T02:03:54Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; Tsai Y.-C.; KUO-HOW HUANG; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2021-03-04T02:36:02Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.;Hsu C.-H.;Huang C.-Y.;Keng H.-Y.;Yu-Chieh Tsai;Huang K.-H.;Cheng A.-L.;Pu Y.-S.; Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; YU-CHIEH TSAI; Huang K.-H.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T01:54:33Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; Tsai Y.-C.; Huang K.-H.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-10-14T02:46:15Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.; Hsu C.-H.; CHAO-YUAN HUANG; Keng H.-Y.; Tsai Y.-C.; Huang K.-H.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2021-02-02T00:46:57Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.;Hsu C.-H.;Huang C.-Y.;Keng H.-Y.;Tsai Y.-C.;Huang K.-H.;Cheng A.-L.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; Tsai Y.-C.; Huang K.-H.; Cheng A.-L.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2022-09-15T01:09:54Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Chia-Chi Lin; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; Tsai Y.-C.; Huang K.-H.; Cheng A.-L.; Pu Y.-S. |
| 國家衛生研究院 |
2015-10 |
Gemcitabine enhances antitumor efficacy of recombinant lipoimmunogen-based immunotherapy
|
Chang, LS;Yan, WL;Chang, YW;Yeh, YC;Chen, HW;Leng, CH;Liu, SJ |
| 國立臺灣大學 |
2007 |
Gemcitabine Is Preferentially Chemosensitive in Cyclin D1 or Cyclin E over-Expressing Human Gastric Cancer Cells
|
沈盈君; 鄭安理; SHEN, YING-CHUN; CHENG, ANN-LII |
| 國家衛生研究院 |
2015-07 |
Gemcitabine plus cisplatin for advanced biliary tract cancer: A systematic review
|
Park, JO;Oh, DY;Hsu, C;Chen, JS;Chen, LT;Orlando, M;Kim, JS;Lim, HY |
| 臺大學術典藏 |
2022-08-19T00:20:46Z |
Gemcitabine plus cisplatin for advanced biliary tract cancer: A systematic review
|
Lim H.Y.; Kim J.S.; Orlando M.; Chen L.-T.; Chen J.-S.; CHIUN HSU; Oh D.-Y.; Park J.O. |
| 臺大學術典藏 |
2015 |
Gemcitabine plus cisplatin for advanced biliary tract cancer: A systematic review
|
Oh D.-Y.; Chiun Hsu; Chen J.-S.; Chen L.-T.; Orlando M.; Kim J.S.; Lim H.Y.; Park J.O.; Park J.O.;Oh D.-Y.;Chiun Hsu;Chen J.-S.;Chen L.-T.;Orlando M.;Kim J.S.;Lim H.Y. |
| 臺大學術典藏 |
2021-01-28T01:06:31Z |
Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: A multicenter prospective Phase II trial
|
Hsieh J.C.; Hsu C.-L.; Ng S.-H.; Wang C.-H.; Lee K.-D.; Lu C.-H.; Chang Y.-F.; Hsieh R.-K.; KUN-HUEI YEH; Hsiao C.-H.; Chen S.-Y.; Shiau C.-Y.; Wang H.-M. |
| 臺大學術典藏 |
2021-02-23T08:26:37Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; SUNG-HSIN KUO; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:26Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; Kuo S.-H.; Hu F.-C.; ANN-LII CHENG; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2022-06-27T07:07:53Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; CHONG-JEN YU; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
